Syncom Formulations (India) Ltd. is a pharmaceutical company known for its diverse portfolio of healthcare products and steady growth in revenues and profitability, making it a stock of interest for long-term investors.
Analysts and market forecasters provide various projected share price targets based on historical performance, sector trends, and growth expectations, giving investors an outlook on potential valuation by 2026, 2027, 2028, 2029, and 2030. These targets help gauge future performance and investment opportunities, though actual outcomes will depend on market conditions and company execution.
Syncom Formulations Share Price Target 2026
Syncom Formulations Limited is gaining investor attention due to its strong presence in the pharmaceutical manufacturing and contract research segments.
The company’s focus on expanding product portfolios, improving operational efficiency, and increasing exports supports long-term growth prospects. With rising demand for affordable healthcare and pharma products in India and overseas, Syncom Formulations is well-positioned for steady performance.
Based on current growth trends and market conditions, the Syncom Formulations share price target for 2026 is expected to be in the range of ₹17 to ₹19, indicating gradual but sustainable upside potential for long-term investors.
Syncom Formulations Share Price Target 2026 Table
| Year | Syncom Formulations Share Price Target 2026 |
| First Target 2026 | Rs 17 |
| Second Target 2026 | Rs 19 |
Syncom Formulations Share Price Target 2027
Syncom Formulations Limited is gaining investor attention due to its strong presence in the pharmaceutical manufacturing and export segment.
The company’s focus on expanding product offerings, improving operational efficiency, and increasing global reach supports long-term growth prospects. With rising demand for affordable healthcare and generic medicines, Syncom Formulations is well-positioned to benefit from industry tailwinds.
Based on current fundamentals and growth expectations, the Syncom Formulations share price target for 2027 is expected to range between ₹21 (lower target) and ₹23 (upper target), depending on market conditions and execution performance.
Syncom Formulations Share Price Target 2027 Table
| Year | Syncom Formulations Share Price Target 2027 |
| First Target 2027 | Rs 21 |
| Second Target 2027 | Rs 23 |
Syncom Formulations Share Price Target 2028
Syncom Formulations Limited is steadily gaining investor interest due to its expanding pharmaceutical portfolio and strong focus on domestic as well as export markets.
The company’s emphasis on quality manufacturing, cost efficiency, and new product launches supports its long-term growth outlook. With rising demand for affordable healthcare and generic medicines in India, Syncom Formulations is well-positioned to benefit from sectoral tailwinds.
Based on current growth trends and improving fundamentals, the Syncom Formulations share price target for 2028 is expected to range between ₹25 (lower target) and ₹27 (upper target), making it a stock to watch for long-term investors.
Syncom Formulations Share Price Target 2028 Table
| Year | Syncom Formulations Share Price Target 2028 |
| First Target 2028 | Rs 25 |
| Second Target 2028 | Rs 27 |
Syncom Formulations Share Price Target 2029
Syncom Formulations Limited is gaining attention among investors due to its steady presence in the pharmaceutical and healthcare segment, supported by a diversified product portfolio and expanding domestic reach.
The company’s focus on improving operational efficiency, cost control, and gradual capacity utilization is expected to support long-term growth. With rising demand for affordable medicines in India, Syncom Formulations may benefit from favorable industry trends.
Based on current business performance and market conditions, the Syncom Formulations share price target for 2029 is expected to range between ₹30 (conservative target) and ₹32 (optimistic target), depending on earnings growth and overall market sentiment.
Syncom Formulations Share Price Target 2029 Table
| Year | Syncom Formulations Share Price Target 2029 |
| First Target 2029 | Rs 30 |
| Second Target 2029 | Rs 32 |
Syncom Formulations Share Price Target 2030
Syncom Formulations Limited is steadily strengthening its presence in the pharmaceutical sector with a diversified product portfolio and expanding domestic and export markets.
The company’s focus on cost-efficient manufacturing, improving margins, and consistent demand for healthcare products supports long-term growth prospects. With rising opportunities in generic medicines and contract manufacturing, Syncom Formulations is expected to benefit from sector-wide expansion.
Based on current growth trends and business outlook, the Syncom Formulations share price target for 2030 is estimated to range between ₹35 (conservative target) and ₹38 (optimistic target), making it an interesting long-term stock to watch.
Syncom Formulations Share Price Target 2030 Table
| Year | Syncom Formulations Share Price Target 2030 |
| First Target 2030 | Rs 35 |
| Second Target 2030 | Rs 38 |
Syncom Formulations Share F.A.Q.
– Who is the owner of Syncom Formulations?
The owner of Syncom Formulations is Kedarmal Shankarlal Bankda.
– Syncom Formulations is associated with the pharmaceutical business.
Syncom Formulations participates in the pharmaceutical industry.
– Where is the headquarters of Syncom Formulations?
The headquarters of Syncom Formulations is in Maharashtra, India.
Conclusion
Considering multiple forecast models and market sentiment, Syncom Formulations’ share price is expected to demonstrate an upward trend through 2030, reflecting optimism around its expanding business and improving financials. While exact figures vary across sources, the overall outlook suggests that long-term investors may see significant value appreciation if the company continues its growth trajectory and capitalizes on industry opportunities. Investors should balance these targets with risk considerations and conduct thorough research before making decisions.
Also read:-